Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review – 2021

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The pharmaceutical and healthcare sector mergers, acquisitions, and investment trend report is an essential source of data and trend analysis on partnerships, licensing mergers, and acquisitions (M&As), and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceutical industry in the year 2021. It also portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceutical industry.

What is the regional level outlook of the global pharmaceutical and healthcare market?

The key regions in the global pharmaceutical and healthcare market are North America, Europe, Asia-Pacific, and the Rest of the World (ROW).

Global Pharmaceutical and Healthcare Market Analysis by Regions

Global Pharmaceutical and Healthcare Market Analysis by Regions

For more regional insights, download a free report sample

What are the key deal types in the global pharmaceutical and healthcare market?

The key deal types in the global pharmaceutical and healthcare market are global M&A deals, equity offering deals, debt offering deals, partnership deals, licensing agreements, private equity deals, and venture capital deals.

Global Pharmaceutical and Healthcare Market Analysis by Deal Types

Global Pharmaceutical and Healthcare Market Analysis by Deal Types

For more deal type insights, download a free report sample

Which are the key market deals in the global pharmaceutical and healthcare market?

The key market deals in the global pharmaceutical and healthcare market are oncology deals, central nervous system deals, infectious disease deals, immunology deals, cardiovascular deals, metabolic disorders deals, and gastrointestinal deals.

Global Pharmaceutical and Healthcare Market Analysis by Market Deals

Global Pharmaceutical and Healthcare Market Analysis by Market Deals

For more market deals insights, download a free report sample

Who are the leading financial advisors in the global pharmaceutical and healthcare market?

Some of the leading financial advisors in the global pharmaceutical and healthcare market are The Goldman Sachs Group Inc, Centerview Partners LLC, J.P. Morgan Securities LLC, Morgan Stanley, Rothschild & Co SCA, Jefferies LLC, SVB Financial Group, Cowen Inc, Bank of America Corp, and Barclays Plc.

The Goldman Sachs Group Inc participated in the major number of M&A deals while Jefferies LLC participated in the major number of the equity offering deals in the pharmaceutical and healthcare industry in 2021.

Leading M&A financial advisors in the global pharmaceutical and healthcare market

Leading M&A financial advisors in the global pharmaceutical and healthcare market

To know more about leading financial advisors, download a free report sample

Market Report Scope

Key regions North America, Europe, Asia-Pacific, and Rest of the World (ROW)
Key deal types Global M&A Deals, Equity Offering Deals, Debt Offering Deals, Partnership Deals, Licensing Agreements, Private Equity Deals, and Venture Capital Deals
Key market deals Oncology Deals, Central Nervous System Deals, Infectious Disease Deals, Immunology Deals, Cardiovascular Deals, Metabolic Disorders Deals, and Gastrointestinal Deals
Leading financial advisors The Goldman Sachs Group Inc, Centerview Partners LLC, J.P. Morgan Securities LLC, Morgan Stanley, Rothschild & Co SCA, Jefferies LLC, SVB Financial Group, Cowen Inc, Bank of America Corp, and Barclays Plc

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genitourinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas that are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals that happened in the pharmaceutical industry.
  • Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

  • Enhance your decision-making capability in a more rapid and time-sensitive manner.
  • Find out the major deal-performing segments for investments in your industry.
  • Evaluate the types of companies that are entering into partnership or licensing agreements, divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving most of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where most of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

2 Pharmaceutical & Healthcare, Global, Deals Summary 12

2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2021 12

2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2021 by Quarter 14

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2021 16

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2021 17

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2021 18

2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2021 19

2.5.1 Thermo Fisher Scientific Acquires PPD 19

2.5.2 CSL to Acquire Vifor Pharma 19

2.5.3 ICON Acquires PRA Health Sciences 20

2.5.4 Merck Acquires Acceleron Pharma 21

2.5.5 Danaher Acquires Aldevron 21

2.5.6 EQT Partners and Goldman Sachs Acquires Parexel International 21

2.5.7 Agnafit Bidco, Advent International, Aurora Investment and GIC to Acquire Swedish Orphan Biovitrum 22

2.5.8 Merck Raises USD8 Billion in Public Offering of Notes 23

2.5.9 Jazz Pharma Acquires GW Pharma 23

2.5.10 Pfizer to Acquire Arena Pharma 24

3 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 25

3.1 Pharmaceuticals & Healthcare, Global, M&A, 2021 25

3.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2021 by Quarter 26

3.1.2 Top M&A Deals in 2021 27

3.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2021 28

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2021 30

3.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2021 by Quarter 31

3.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2021 32

3.2.3 Top IPOs in 2021 33

3.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2021 34

3.2.5 Top Secondary Offerings in 2021 35

3.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2021 35

3.2.7 Top PIPE Deals in 2021 36

3.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2021 37

3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2021 38

3.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2021 by Quarter 39

3.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2021 40

3.3.3 Top Public Debt Offerings in 2021 41

3.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2021 42

3.3.5 Top Private Debt Placements in 2021 43

3.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2021 43

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2021 45

3.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2021 by Quarter 46

3.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2021 47

3.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2021 49

3.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2021 50

3.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number of Deals, 2021 51

3.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2021 52

3.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2021 53

3.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2021 54

3.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2021 55

3.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2021 55

3.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2021 56

3.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2021 by Quarter 57

3.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2021 58

3.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2021 59

3.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2021 60

3.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2021 61

3.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2021 62

3.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2021 64

3.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2021 65

3.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2021 66

3.5.10 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2021 66

3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2021 67

3.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2021 by Quarter 68

3.6.2 Top Private Equity Deals in 2021 69

3.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2021 70

3.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2021 71

3.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2021 by Quarter 72

3.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2021 73

3.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2021 73

3.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2021 74

3.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 75

3.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2021 76

3.7.7 Top Venture Financing Deals in 2021 78

4 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 79

4.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2021 79

4.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2021 by Quarter 80

4.1.2 Oncology – Deals of the Year 81

4.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2021 84

4.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2021 by Quarter 85

4.2.2 Central Nervous System – Deals of the Year 87

4.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2021 90

4.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2021 by Quarter 91

4.3.2 Infectious Disease – Deals of the Year 92

4.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2021 96

4.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2021 by Quarter 97

4.4.2 Immunology – Deals of the Year 98

4.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2021 102

4.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2021 by Quarter 103

4.5.2 Cardiovascular – Deals of the Year 104

4.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2021 107

4.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2021 by Quarter 108

4.6.2 Metabolic Disorders – Deals of the Year 109

4.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2021 112

4.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2021 by Quarter 113

4.7.2 Gastrointestinal – Deals of the Year 114

5 Pharmaceuticals & Healthcare, Deal Summary, By Geography 117

5.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2021 117

5.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2021 by Quarter 118

5.1.2 North America – Deals of the Year 119

5.2 Pharmaceuticals & Healthcare, European Region Deals, 2021 122

5.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2021 by Quarter 123

5.2.2 Europe – Deals of the Year 124

5.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2021 127

5.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2021 by Quarter 128

5.3.2 Asia-Pacific – Deals of the Year 129

5.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2021 133

5.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2021 by Quarter 134

5.4.2 Rest of the World – Deals of the Year 135

6 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 137

6.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2021 137

6.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2021 139

7 Further Information 141

7.1 Methodology 141

7.2 About GlobalData 142

7.3 Contact Us 142

7.4 Disclosure information 142

7.5 Disclaimer 143

Table

List of Tables

Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 13

Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021 15

Table 3: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (%), 2021 17

Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2021 18

Table 5: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 26

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 27

Table 7: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2021 27

Table 8: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021 29

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 31

Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 32

Table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 33

Table 12 Pharmaceuticals & Healthcare, Global, Top IPOs, 2021 33

Table 13: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 34

Table 14: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2021 35

Table 15: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 36

Table 16: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2021 36

Table 17: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2021 37

Table 18: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 39

Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 40

Table 20: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 41

Table 21: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2021 41

Table 22: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 42

Table 23: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2021 43

Table 24: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2021 44

Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2017 – 2021 45

Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2021–Q4 2021 46

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021 48

Table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2021 49

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2021 51

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2021 52

Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2021 54

Table 32: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2021 54

Table 33: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2021 55

Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2021 55

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 56

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021–Q4 2021 57

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021 58

Table 38: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2021 59

Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2021 61

Table 40: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2017 – Q4 2021 63

Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2021 65

Table 42: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2021 65

Table 43: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2021 66

Table 44: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2021 66

Table 45: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 67

Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 68

Table 47: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2021 69

Table 48: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2021 70

Table 49: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 71

Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 72

Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2021 74

Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2021 75

Table 53: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2021 75

Table 54: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2021 77

Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2021 78

Table 56: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 80

Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 81

Table 58: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 85

Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 86

Table 60: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 91

Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 92

Table 62: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 97

Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 98

Table 64: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 103

Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 104

Table 66: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 108

Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 109

Table 68: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 113

Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 114

Table 70: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 118

Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2021–Q4 2021 119

Table 72: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 123

Table 73: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021 124

Table 74: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 128

Table 75: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021 129

Table 76: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 – 2021 134

Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2021–Q4 2021 135

Table 78: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2021 138

Table 79: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2021 140

Figures

List of Figures

Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2017- 2021 12

Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021 14

Figure 3: Pharmaceuticals & Healthcare, Global, Number of Deals (%), 2021 16

Figure 4: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2021 17

Figure 5 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2017 – 2021 25

Figure 6 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 26

Figure 7: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021 28

Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2017 – 2021 30

Figure 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 31

Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2017 – 2021 32

Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2017 – 2021 34

Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2017 – 2021 35

Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021 37

Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2017 – 2021 38

Figure 15: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 39

Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2017 – 2021 40

Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2017 – 2021 42

Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021 43

Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2017 – 2021 45

Figure 20: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 46

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2021 47

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021 47

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2021 49

Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2021 50

Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2021 51

Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2021 52

Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2021 53

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2017 – 2021 56

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 57

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021 58

Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2021 59

Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2021 60

Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number of Deals, 2021 61

Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2021 62

Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2021 64

Figure 36: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2017 – 2021 67

Figure 37: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 68

Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021 70

Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2017 – 2021 71

Figure 40: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 72

Figure 41: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2021 73

Figure 42: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2021 73

Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021 74

Figure 44: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2021 76

Figure 45: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2017 – 2021 79

Figure 46: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 80

Figure 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2021, 2017 – 2021 84

Figure 48: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 85

Figure 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2017 – 2021 90

Figure 50: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021 91

Figure 51: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2017 – 2021 96

Figure 52: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 97

Figure 53: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2017 – 2021 102

Figure 54: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 103

Figure 55: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2017 – 2021 107

Figure 56: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 108

Figure 57: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 – 2021 112

Figure 58: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021 113

Figure 59: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), 2017 – 2021 117

Figure 60: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2021–Q4 2021 118

Figure 61: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2017 – 2021 122

Figure 62: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2021–Q4 2021 123

Figure 63: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2017 – 2021 127

Figure 64: Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2021–Q4 2021 128

Figure 65: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2017 – 2021 133

Figure 66: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2021–Q4 2021 134

Figure 67: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2021 137

Figure 68: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2021 139

Frequently asked questions

Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review – 2021 thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review – 2021 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review – 2021 in real time.

  • Access a live Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review – 2021 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.